Table 2.
Univariate and multivariate analyses of clinicopathologic parameters associated with progression-free survival and overall survival.
| Parameters | Progression-free survival | Overall survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Gender (Female vs Male) | 1.029 | 0.599-1.768 | 0.918 | 0.958 | 0.558-1.646 | 0.877 | ||||||
| Age (<60 vs ≥60) | 1.005 | 0.568-1.780 | 0.985 | 0.965 | 0.573-1.791 | 0.965 | ||||||
| Tumor size (≥5 cm vs <5 cm) | 1.011 | 0.582-1.758 | 0.969 | 1.001 | 0.576-1.740 | 0.997 | ||||||
| Tumor differentiation (Poor vs Moderate/Well) | 1.030 | 0.585-1.813 | 0.919 | 0.948 | 0.579-1.793 | 0.948 | ||||||
| T stage (T3-4 vs T1-2) | 1.869 | 1.048-3.335 | 0.034 | 0.668 | 0.289-1.542 | 0.344 | 1.834 | 1.033-3.256 | 0.038 | 0.675 | 0.287-1.589 | 0.368 |
| LNM (N2-3 vs N0-1) | 1.609 | 0.936-2.766 | 0.085 | 1.580 | 0.920-2.714 | 0.097 | ||||||
| TNM stagea (III/IV vs I/II) | 2.226 | 1.262-3.925 | 0.006 | 1.129 | 0.480-2.654 | 0.781 | 2.201 | 1.250-3.877 | 0.006 | 1.061 | 0.441-2.554 | 0.894 |
| Intraoperative DM (Presence vs Absence) | 6.452 | 2.588-16.083 | 0.000 | 6.400 | 2.251-18.198 | 0.000 | 6.269 | 2.525-15.562 | 0.000 | 7.583 | 2.524-22.782 | 0.000 |
| CEA (High vs Low) | 0.800 | 0.442-1.446 | 0.460 | 0.814 | 0.450-1.472 | 0.496 | ||||||
| CA19-9 (High vs Low) | 1.228 | 0.707-2.131 | 0.466 | 1.249 | 0.719-2.170 | 0.429 | ||||||
| Postoperative PM (Presence vs Absence) | 6.873 | 3.530-13.384 | 0.000 | 6.248 | 2.998-13.020 | 0.000 | 6.494 | 3.391-12.434 | 0.000 | 5.850 | 2.817-12.146 | 0.000 |
| BGN (High vs Low) | 4.095 | 1.958-8.565 | 0.000 | 4.733 | 2.153-10.408 | 0.000 | 3.910 | 1.877-8.145 | 0.000 | 4.851 | 2.156-10.914 | 0.000 |
| FAP (High vs Low) | 2.459 | 1.318-4.591 | 0.005 | 1.809 | 0.899-3.640 | 0.096 | 2.497 | 1.328-4.696 | 0.005 | 2.018 | 0.988-4.120 | 0.054 |
Notes: boldface indicates P < 0.05; a, the 8th edition of the AJCC Cancer Staging Manual. Abbreviations: BGN, biglycan; FAP, fibroblast activation protein; T stage, tumor invasion stage; LNM, lymph node metastasis; TNM, tumor-node-metastasis; DM, distant metastasis; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; PM, peritoneal metastasis.